Supplementary Materials

The PDF file includes:

  • Fig. S1. Schematic overview of the four galidesivir dosing studies.
  • Fig. S2. Detection of ZIKV shedding in saliva and urine after postexposure treatment (study 1).
  • Fig. S3. Reduction of ZIKV RNA in bodily fluids after galidesivir prophylaxis (study 1).
  • Fig. S4. Activation of NK cell subsets after ZIKV infection in galidesivir-treated macaques (study 1).
  • Fig. S5. Neutralizing antibody development after galidesivir-treated ZIKV infection (study 1).
  • Fig. S6. Protection against heterologous ZIKV challenge in macaques treated with galidesivir during primary infection (study 1).
  • Fig. S7. Cellular immune activation after secondary ZIKV challenge in galidesivir-treated macaques (study 1).
  • Fig. S8. The percentage of ZIKV RNA-positive plasma samples in groups of animals treated with decreasing doses of galidesivir after infection (study 2).
  • Fig. S9. Neutralizing antibody titers measured by PRNT90 after ZIKV infection (study 2).
  • Fig. S10. The percentage of ZIKV RNA–positive plasma and CSF samples over time (days) after subcutaneous infection with a ZIKV Puerto Rico isolate (study 3).
  • Fig. S11. Intravaginal titration of ZIKV in rhesus macaques.
  • Fig. S12. The percentage of longitudinal ZIKV RNA–positive samples after intravaginal infection (study 4).
  • Fig. S13. Estimated drug efficiency.
  • Fig. S14. Estimated individual viral loads for ZIKV-infected macaques in each galidesivir treatment study.
  • Table S1. Neutralizing antibody titers measured by PRNT90.
  • Table S2. Mean galidesivir maternal:litter plasma concentration ratio on the last day of dosing.
  • Table S3. Shown for each drug dosing regimen is the estimated population mean of drug efficiency (ε) and the corresponding expected drop (log10) in viral load in a steady-state system.
  • Legend for data file S1

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Individual-level data for all figures.